<DOC>
	<DOCNO>NCT02444221</DOCNO>
	<brief_summary>To discover outcome patient treat Rivaroxaban atrial fibrillation least one additional investigator-determined risk factor stroke real-life practice .</brief_summary>
	<brief_title>Rivaroxaban Evaluation Real Life Settings</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Written inform consent Age 18 year New diagnosis nonvalvular atrial fibrillation ( diagnose within last 6 week ) least one additional investigatordetermined risk factor stroke regardless therapy No followup envisage possible within enrol hospital associate family practitioner . Patients transient AF secondary reversible cause . According European Directive 2001/20/EC , patient recruit controlled clinical trial eligible registry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Stroke</keyword>
</DOC>